AIM: To review the clinical use and the effectiveness of tamoxifen in patients with advanced or recurrent ovarian cancer.
METHODS: A retrospective review of clinical records was conducted in patients who received tamoxifen for the treatment of ovarian cancer between 2002 and 2016 . We reviewed the clinical setting that it was given, duration of use, patients' tolerability, clinical benefit and progression-free survival . We also attempted to identify predictive markers for response .
RESULTS: A total of 92 patients received tamoxifen during this 15-year period . The patients received a median of 2.5 lines of chemotherapy before switching to tamoxifen, and they remained on tamoxifen for a median of 5.6 months (range 0-85 months), with 24 patients receiving it for more than 12 months . Seventy-six patients continued on tamoxifen for more than 2 months . In this group , 75 patients had an evaluable response, either by CA 125 or clinically and clinical benefit rate (defined as complete, partial response and static disease) was seen in 42 patients (56 %), with majority of patients having static disease . The median progression-free survival was 5.3 months (95% confidence interval , 2.6-8.1). Tamoxifen was well tolerated . Hormone receptor status was not demonstrated to predict response .
CONCLUSION: Patients with advanced ovarian cancer who have failed previous lines of chemotherapy may achieve static disease with tamoxifen with minimal side effects . Tamoxifen may still have a role in the era of molecular target therapy.